Description
Co-Amlessa Tablets 4 mg/1.25 mg/10 mg
Ingredients:
- Perindopril tert-butylamine 4 mg
- Indapamide 1.25 mg
- Amlodipine 10 mg
Mechanism of Action:
Co-Amlessa combines three antihypertensive agents: perindopril, an ACE inhibitor; indapamide, a thiazide-like diuretic; and amlodipine, a calcium channel blocker. This combination targets multiple pathways involved in blood pressure regulation.
Pharmacological Properties:
The synergistic effects of perindopril, indapamide, and amlodipine result in effective blood pressure reduction by acting on different mechanisms, leading to improved cardiovascular outcomes.
Indications for Use:
Co-Amlessa tablets are indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy with individual components.
Contraindications:
Avoid Co-Amlessa if allergic to any ingredient, have a history of angioedema related to ACE inhibitor therapy, or during pregnancy.
Side Effects:
Common side effects may include dizziness, headache, and edema. Consult a healthcare provider for a complete list of adverse reactions.
Usage Instructions:
Take one tablet daily in the morning before a meal with a full glass of water. Swallow the tablet whole; do not crush or chew.
Benefits Compared to Analogues:
Co-Amlessa’s unique combination offers superior blood pressure control compared to individual therapies, reducing the risk of cardiovascular events and improving patient outcomes.
Suitable Patient Groups:
Co-Amlessa is suitable for adult patients with hypertension. Dosage adjustments may be necessary for specific patient populations such as the elderly or those with renal impairment.
Storage and Shelf Life:
Store Co-Amlessa in a cool, dry place away from direct sunlight. Check the packaging for the expiration date and do not use beyond the stated shelf life.
Packaging Description:
Co-Amlessa is available in a package containing 30 tablets. Each tablet is individually sealed to maintain product integrity.
Clinical Evidence and Effectiveness:
Studies have shown that Co-Amlessa effectively reduces both systolic and diastolic blood pressure compared to monotherapy with individual components. The combination therapy provides better blood pressure control and reduces the risk of cardiovascular events.
